Literature DB >> 9711711

The caudalis DREZ for facial pain.

D E Bullard1, B S Nashold.   

Abstract

During a 3-year period, 25 caudalis dorsal root entry zone (DREZ) operations were done for severe, facial pain. Intraoperative brainstem recordings were done before and after DREZ in all patients. Primary diagnosis included refractory trigeminal neuralgia, atypical headaches or facial pain, posttraumatic closed head injuries, postsurgical anesthesia dolorosa, multiple sclerosis, brainstem infarction, postherpetic neuralgia and cancer-related pain. At the time of discharge, good to excellent pain relief was present in 24/25 patients and fair relief in 1. At 1 month, 19/25 (76%) patients had good to excellent results and at 3 months following surgery, 17/25 (68%) continued to have good to excellent pain relief. One year following surgery, 18 patients could be evaluated, 12/18 (67%) still considered their relief as good to excellent, 2 fair and 4 poor. Transient postoperative ataxia was present in 15/25 patients (60%), but was largely resolved at 1 months. In 3/18 (17%) patients, a degree of ataxia was still present at 1 year although in none was it disabling. Two patients had transient diplopia, and 3 had increased corneal anesthesia with 1 later developing a keratitis. No surgical or postsurgical mortality was noted. This procedure has proven to be a satisfactory treatment for many patients with debilitating facial pain syndromes with acceptable morbidity.

Entities:  

Mesh:

Year:  1997        PMID: 9711711     DOI: 10.1159/000099918

Source DB:  PubMed          Journal:  Stereotact Funct Neurosurg        ISSN: 1011-6125            Impact factor:   1.875


  2 in total

Review 1.  Trigeminal neuralgia and other neuropathic pain syndromes of the head and face.

Authors:  W Jeffrey Elias; Kim J Burchiel
Journal:  Curr Pain Headache Rep       Date:  2002-04

2.  The Evolution of Neuromodulation in the Treatment of Chronic Pain: Forward-Looking Perspectives.

Authors:  Michael A Fishman; Ajay Antony; Michael Esposito; Timothy Deer; Robert Levy
Journal:  Pain Med       Date:  2019-06-01       Impact factor: 3.750

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.